After generating interest from the likes of Pfizer and GSK, Quotient Therapeutics’ somatic genomics platform has attracted ...

The somatic genomics approach analyses naturally accumulated genetic mutations within individual patient tissue.

Somatic genetic mutations naturally accumulate over a lifetime, resulting in trillions of different genomes within an individual. Through its platform, Quotient interrogates patient tissue for these ...

Merck (known as MSD outside the US and Canada) has agreed on a multi-year research collaboration with Quotient Therapeutics in a deal that could be worth up to $2.2bn. Through the collaboration, the ...

High-sensitivity sequencing of recurrent, cell-type–specific variants aims to strengthen causal inference versus germline ...

IBD is a key R&D focus for MSD, whose pipeline in the indication is currently led by tulisokibart, an anti-TL1A antibody in ...

Christine Allen, CEO and Co-Founder of Intrepid Labs, and Andy Lewis, CSO at Quotient Sciences, highlight their strategic ...

Quotient, which originated as the consumer-facing Coupons.com in the late ’90s, is pushing deeper into programmatic media. The company has launched the Quotient Media Exchange (QMX), a digital media ...